Last edition
News about "Dr. Rajeev Singh Raghuvanshi"
Monitor NDMA Impurity in Ranitidine Formulation: DCGI Directs Indian Drugmakers
The DCGI has instructed drug controllers of all States and Union Territories to ensure that manufacturers under their jurisdiction monitor the presence of N-Nitrosodimethylamine(NDMA) - a potentially carcinogenic impurity – in the active pharmaceutical ingredient (API) and formulation of the antacid Ranitidine.
Dr. Rajeev Singh Raghuvanshi | 31/07/2025 | By Dineshwori | 391
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members